← Browse by Condition
Medical Condition
esophageal cancer
Total Trials
20
Recruiting Now
20
Trial Phases
Phase 2, Phase 3, Phase 1
NCT03736863 Phase 2
Recruiting
A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Enrollment
147 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT04280822 Phase 3
Recruiting
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
Enrollment
400 pts
Location
China
Sponsor
Henan Cancer Hospital
NCT05967910
Recruiting
The Effect of Chronic Stress on Efficacy of ICIs in Esophageal Cancer Patients (STRESS-ESCA Study)
Enrollment
200 pts
Location
China
Sponsor
Second Xiangya Hospital of Cen...
NCT06414902 Phase 1
Recruiting
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
Enrollment
60 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT05937477
Recruiting
Developing Artificial Intelligence-based Algorism to Predict Side Effects and Symptoms From Chemotherapy
Enrollment
500 pts
Location
South Korea
Sponsor
Sehhoon Park
NCT06047379 Phase 1, Phase 2
Recruiting
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Enrollment
134 pts
Location
United States
Sponsor
Neonc Technologies, Inc.
NCT07455019 Phase 2
Recruiting
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
Enrollment
28 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT06872515
Recruiting
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
Enrollment
20 pts
Location
United States
Sponsor
University of Pittsburgh
NCT06979869
Recruiting
Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Esophageal Carcinoma
Enrollment
300 pts
Location
China
Sponsor
Xijing Hospital
NCT03787056
Recruiting
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Enrollment
410 pts
Location
France
Sponsor
Hospices Civils de Lyon
NCT04135664 Phase 3
Recruiting
Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
Enrollment
176 pts
Location
China
Sponsor
Shanghai Chest Hospital
NCT05517811
Recruiting
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
Enrollment
400 pts
Location
United States
Sponsor
University of Colorado, Denver
NCT05547529 Phase 3
Recruiting
The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer
Enrollment
156 pts
Location
Russia
Sponsor
Blokhin's Russian Cancer Resea...
NCT06792786
Recruiting
A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring
Enrollment
30 pts
Location
China
Sponsor
The Central Hospital of Lishui...
NCT07354295
Recruiting
Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer （Radiogenomics-Esophagus）
Enrollment
1,500 pts
Location
China
Sponsor
Shu Peng
NCT06755866
Recruiting
DCE-MRI Based on 4D Free Breathing for Predicting Preoperative Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Enrollment
135 pts
Location
China
Sponsor
Yunnan Cancer Hospital
NCT05865743 Phase 3
Recruiting
Perioperative SDD to Prevent Infectious Complications After Esophagectomy
Enrollment
854 pts
Location
Belgium, Netherlands
Sponsor
Radboud University Medical Cen...
NCT05443841
Recruiting
Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
Enrollment
385 pts
Location
China
Sponsor
Fudan University
NCT07054086
Recruiting
Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Enrollment
30 pts
Location
China
Sponsor
Shanghai Zhongshan Hospital
NCT05357846 Phase 3
Recruiting
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Enrollment
422 pts
Location
China
Sponsor
Sun Yat-sen University